Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis

J Am Coll Cardiol. 2014 Feb 18;63(6):537-8. doi: 10.1016/j.jacc.2013.09.057. Epub 2013 Oct 30.

Authors

Bertram Pitt¹, Patrick Rossignol²

Affiliations

¹ University of Michigan School of Medicine, Ann Arbor, Michigan.
² Inserm 9501 and 1116, Centre d'Investigations Cliniques, Nancy, France; CHU Nancy, Institut Lorrain du Coeur et des Vaisseaux, Vandoeuvre lès Nancy, Nancy, France; Université de Lorraine, Nancy, France; Association Lorraine pour le Traitement de l'Insuffisance Rénale, Vandoeuvre lès Nancy, Nancy, France. Electronic address: p.rossignol@chu-nancy.fr.

PMID: 24184253
DOI: 10.1016/j.jacc.2013.09.057

No abstract available

Keywords: cardiovascular and cerebrovascular event; hemodialysis; spironolactone.

Publication types

Editorial
Comment

MeSH terms

Cardiovascular Diseases / prevention & control*
Female
Humans
Kidney Failure, Chronic / complications*
Male
Mineralocorticoid Receptor Antagonists / therapeutic use*
Spironolactone / therapeutic use*

Substances

Mineralocorticoid Receptor Antagonists
Spironolactone